Shares of Eli Lilly and Novo Nordisk dropped Friday, after President Donald Trump said his administration…
Category: News
NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies
Dario Amodei, Anthropic CEO,speaking on CNBC’s Squawk Box outside the World Economic Forum in Davos, Switzerland…
Integral Consulting and Verdi Technology Form Strategic Partnership to Advance Occupational Health, Safety, and Chemical Risk Management Solutions for EV and Lithium-Battery Value Chain
The logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic…
ADC Therapeutics to Present at November Investor Conferences
LAUSANNE, Switzerland, Oct. 27, 2025 /PRNewswire/ — ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader…
National Center of Technology Innovation for Dairy Debuts at the IDF World Dairy Summit, Showcasing Innovation to Drive Sustainability
SANTIAGO, Chile, Oct. 27, 2025 /PRNewswire/ — The highly anticipated 2025IDF World Dairy Summit took place…
Alphyn Expands Patent Estate with New U.S. Patent for Atopic Dermatitis Therapeutic
Patent covers active pharmaceutical ingredient with protection until 2041 ANNAPOLIS, Md., Oct. 27, 2025 /PRNewswire/ –Alphyn,…
TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn’s disease at two years
Clinical remission rates were over 85% for both TREMFYA® maintenance doses at 96 weeks in both…
Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis
Building on 12-week findings, icotrokinra demonstrated clinically meaningful outcomes at Week 28 with 31.7% of patients…
New Study Demonstrates Accuracy of Two Quest AD-Detect® Tests for Alzheimer’s Disease Diagnosis
The Quest AD-Detect® blood-based test panels deliver confirmatory accuracy, potentially supporting reduced reliance on PET-imaging confirmation…
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2025 Financial Results
ATLANTA, Oct. 23, 2025 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery…